Patients with rheumatoid arthritis in clinical care

被引:58
作者
Smolen, JS
Aletaha, D
机构
[1] Univ Vienna, Vienna Gen Hosp Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria
[2] Lainz Hosp, Dept Med 2, Vienna, Austria
关键词
D O I
10.1136/ard.2003.012575
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Taken together, our current clinical armamentarium to follow the course of RA offers several disease activity measures. Evaluation of radiographic destruction, but also of anatomical changes such as malalignment,77 can serve as outcome measure, because these changes best reflect the damage related to the pathological process in and around the joints; whether radiological changes can be reversible, is still a matter of debate. 78 Assessment of function reflects the combination of disease activity and damage. Questionnaires or other instruments which only determine functional improvement due to irreversible damage are not (yet) available. However, their development could lead to interesting, new clinical insights. Likewise, basic science has not yet provided us with tests that reflect the destructive process reliably. Measuring disease activity by surrogate measures such as the acute phase proteins does not reflect destruction at a single point in time. In conclusion, assessment of disease activity, damage, and functional capacity are equally important also in clinical practice; RA, if insufficiently controlled, may be a highly destructive disease. Achieving low disease activity, ideally a remission-like state, is pivotal to improving prognosis. 79 Current treatments and early institution of DMARDs allow this aim to be accomplished in many patients. However, decisions to switch (or to maintain) treatment require recording of the patients' clinical status, and in many healthcare systems the use of costly treatments, as increasingly employed, requires justification which, again, can only come from recorded data. 18 Rather than guessing disease activity and quality of life, providing evidence will validate decisions and improve quality of care. A combination of a more physician centred activity score, such as the SDAI or similar, with a patient centred functional measure, such as the HAQ or similar, in conjunction with an occasional evaluation of the radiographic situation, will give all necessary information for the longitudinal observation of patients' disease state in clinical practice. The tools are available and so relatively easy to use.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 88 条
  • [1] Aletaha D, 2002, J RHEUMATOL, V29, P1631
  • [2] Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years
    Aletaha, D
    Eberl, G
    Nell, VPK
    Machold, KP
    Smolen, JS
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (07) : 630 - 634
  • [3] Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: Clinical evaluation and cost analysis
    Aletaha, D
    Smolen, JS
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (02): : 181 - 188
  • [4] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    Bathon, JM
    Martin, RW
    Fleischmann, RM
    Tesser, JR
    Schiff, MH
    Keystone, EC
    Genovese, MC
    Wasko, MC
    Moreland, LW
    Weaver, AL
    Markenson, J
    Finck, BK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1586 - 1593
  • [5] Beaton DE, 2001, ARTHRIT RHEUM-ARTHR, V45, P270, DOI 10.1002/1529-0131(200106)45:3<270::AID-ART260>3.3.CO
  • [6] 2-K
  • [7] Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research
    Beaton, DE
    Boers, M
    Wells, GA
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (02) : 109 - 114
  • [8] Beaton DE, 2001, J RHEUMATOL, V28, P400
  • [9] BOERS M, 1994, J RHEUMATOL, V21, P86
  • [10] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M
    Verhoeven, AC
    Markusse, HM
    vandeLaar, MAFJ
    Westhovens, R
    vanDenderen, JC
    vanZeben, D
    Dijkmans, BAC
    Peeters, AJ
    Jacobs, P
    vandenBrink, HR
    Schouten, HJA
    vanderHeijde, DMFM
    Boonen, A
    vanderLinden, S
    [J]. LANCET, 1997, 350 (9074) : 309 - 318